Compare META & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | META | NVS |
|---|---|---|
| Founded | 2004 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3T | 286.9B |
| IPO Year | 2012 | N/A |
| Metric | META | NVS |
|---|---|---|
| Price | $674.89 | $149.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 40 | 5 |
| Target Price | ★ $838.29 | $144.00 |
| AVG Volume (30 Days) | ★ 14.5M | 1.4M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | 0.31% | ★ 2.03% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 23.49 | N/A |
| Revenue | ★ $40,653,000,000.00 | N/A |
| Revenue This Year | $26.98 | $2.34 |
| Revenue Next Year | $18.20 | $5.14 |
| P/E Ratio | $28.55 | ★ $23.13 |
| Revenue Growth | ★ 47.09 | N/A |
| 52 Week Low | $479.80 | $108.53 |
| 52 Week High | $796.25 | $170.46 |
| Indicator | META | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 66.72 | 41.00 |
| Support Level | $633.38 | $145.30 |
| Resistance Level | $674.35 | $158.80 |
| Average True Range (ATR) | 17.63 | 2.11 |
| MACD | 13.65 | 0.09 |
| Stochastic Oscillator | 97.11 | 18.01 |
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.